Skip to main content

Table 3 Univariate Cox proportional hazard model of variables associated with CV death and MACE in the study population

From: Lipoprotein-associated phospholipase A2 predicts cardiovascular death in patients on maintenance hemodialysis: a 7-year prospective cohort study

Variable

CV death

MACE

HR(95% CI)

P value

HR(95% CI)

P value

Age(years)

1.05(1.03–1.07)

 < 0.001

1.06(1.04–1.08)

 < 0.001

Dialysis vintage (month)

0.99(0.98–1.00)

0.06

0.99(0.99–1.00)

0.096

Sex (male vs female)

1.34(0.86–2.11)

0.2

1.22(0.80–1.87)

0.349

Vascular access (catheter vs arteriovenous fistula)

0.48(0.30–0.76)

0.002

0.41(0.26–0.62)

 < 0.001

Body mass index (kg/m2)

1.07(1.00–1.13)

0.049

1.05(0.99–1.11)

0.111

Smoking history (%)

1.38(0.66–2.87)

0.387

1.19(0.58–2.47)

0.634

Hypertension

1.55(0.21–11.47)

0.67

1.98(0.63–6.27)

0.244

Diabetes

2.23(1.39–3.57)

0.001

2.02(1.29–3.16)

0.002

Coronary artery disease

2.81(1.59–4.94)

 < 0.001

2.57(1.50–4.43)

0.001

Cerebrovascular event

1.24(0.59–2.58)

0.568

1.21(0.61–2.42)

0.58

ACEI

0.65(0.36–1.17)

0.152

0.61(0.34–1.07)

0.085

ARB

0.82(0.51–1.32)

0.417

0.75(0.48–1.19)

0.222

CCB

0.84(0.51–1.38)

0.484

0.93(0.58–1.51)

0.783

β-blockers

0.86(0.55–1.36)

0.521

0.85(0.55–1.30)

0.444

Statin

1.07(0.61–1.87)

0.828

1.13(0.68–1.90)

0.637

Aspirin

1.12(0.69–1.82)

0.656

1.04(0.66–1.65)

0.867

Lp-PLA2 > 481.2U/L

2.15(1.33–3.46)

0.002

1.81(1.17–2.80)

0.007

Lp-PLA2 (per 100 U/L)

1.18(1.05–1.32)

0.004

1.14(1.02–1.27)

0.018

Hemoglobin (g/L)

1.00(0.99–1.01)

0.984

0.99(0.99–1.01)

0.929

Platelet (× 109/L)

1.00(0.99–1.01)

0.408

1.00(0.99–1.00)

0.402

Albumin (g/L)

0.94(0.88–0.99)

0.043

0.94(0.88–0.99)

0.046

Pre-albumin (per 0.1 g/L)

0.11(0.01–1.81)

0.122

0.08(0.01–1.11)

0.06

Urea (mmol/L)

0.98(0.96–1.02)

0.506

0.99(0.95–1.01)

0.259

Serum creatinine (μmol/L)

0.99(0.98–0.99)

 < 0.001

0.99(0.98–1.00)

0.001

Uric acid (mmol/L)

0.99(0.98–0.99)

0.009

0.99(0.98–0.99)

0.01

Total cholesterol (mmol/L)

1.015(0.83–1.24)

0.878

1.02(0.86–1.21)

0.827

LDL-c (mmol/L)

0.99(0.79–1.14)

0.931

0.98(0.80–1.21)

0.881

HDL-c (mmol/L)

1.17(0.61–2.23)

0.646

1.04(0.56–1.93)

0.901

Apo-B(g/L)

0.91(0.35–2.34)

0.847

1.02(0.42–2.44)

0.971

Apo-A(g/L)

0.76(0.32–1.79)

0.529

0.75(0.34–1.67)

0.483

Triglyceride (mmol/L)

0.98(0.81–1.19)

0.848

1.02(0.86–1.21)

0.827

Homocysteine (μmol/L)

0.53(0.21–1.30)

0.166

0.74(0.33–1.66)

0.467

Lipoprotein(a) (nmol/L)

1.21(0.73–2.00)

0.465

1.40(0.86–2.25)

0.172

NT-proBNP (pg/ml)

2.08(1.33–3.27)

0.001

1.87(1.22–2.85)

0.004

Cardiac troponin T (ng/ml)

7.30(3.27–16.32)

 < 0.001

6.52(3.06–13.87)

 < 0.001

High-sensitivity C-reactive protein(mg/L)

1.44(0.97–2.15)

0.072

1.43(0.98–2.07)

0.063

  1. ACEI Angiotensin-converting-enzyme inhibitor, ARB Angiotensin II receptor blocker, CCB Calcium channel blocker, HDL-c High-density lipoprotein cholesterol, LDL-c Low-density lipoprotein cholesterol